You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Soluble PD-1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma Trial

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +10 more
  • Antineoplastic Immune Cell
  • +4 more
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Aug 12, 2022

Soluble Programmed Death-1 in Predicting Progression of

Recruiting
  • Nontuberculous Mycobacterial Lung Disease
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jan 18, 2023

    HNSCC Trial in Worldwide (Eftilagimod alpha, Pembrolizumab)

    Recruiting
    • HNSCC
    • Birmingham, Alabama
    • +28 more
    Nov 29, 2022

    Developmental Endothelial Locus-1, Platelet Count, and Soluble

    Not yet recruiting
    • Overweight and Obesity
    • Platelet count
    • +2 more
    • Aswan, Egypt
      Aswan University Hospital
    May 17, 2023

    Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

    Not yet recruiting
    • Lung Neoplasm
    • +2 more
    • Tumor samples
    • Bordeaux, France
      CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
    Aug 28, 2023

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023

    Soluble Programmed Death 1 isDiagnostic Biomarker of ILD in

    Not yet recruiting
    • Rheumatoid Arthritis
    • soluble programmed death 1biomarker
    • (no location specified)
    Jan 11, 2022

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Immune Function and PD-1 Antibody Therapy Efficacy Predictors on

    Recruiting
    • Secondary Hemophagocytic Lymphohistiocytosis
    • Chronic Active Epstein-Barr Virus Infection
    • No intervention
    • Beijing, Beijing, China
      Beijing Friendship Hospital, Capital Medical University
    May 2, 2023

    Monitoring T Cell Responses in Melanoma, Lung and Other Cancer

    Recruiting
    • Clinical Stage III Cutaneous Melanoma AJCC v8
    • +9 more
    • Biospecimen Collection
    • Electronic Health Record Review
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Oct 4, 2023

    Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

    Recruiting
    • Lung Cancer
    • Yiwu, Zhejiang, China
      The Fourth Affiliated Hospital of Zhejiang University
    Dec 16, 2022

    Maternal Soluble Trigger Receptor Expressed on Myeloid Cells-1

    Recruiting
    • Placenta Accreta, Third Trimester
      • Konya, Turkey
        Necmettin Erbakan University Meram Medicine Faculty
      May 11, 2022

      Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

      Recruiting
      • Digestive System Cancers
      • Beijing, China
        Peking University Cancer Hospital
      Oct 25, 2023

      Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

      Completed
      • Metastatic Colorectal Adenocarcinoma
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Sep 2, 2023

      Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • iNKT Cells
      • +2 more
      • Beijing, Beijing, China
        Beijing Youan Hospital,Capital Medical University
      Jul 24, 2023

      Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

      Not yet recruiting
      • Advanced Non Small Cell Lung Cancer
      • (no location specified)
      Oct 24, 2023

      Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)

      Recruiting
      • Colorectal Liver Metastases
      • Radiation: High- and Low-dose radiotherapy
      • PD-1 Inhibitors
      • Nanjing, Jiangsu, China
        Jiangsu Cancer Hospital
      Sep 13, 2023

      Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

      Recruiting
      • Hepatocellular Carcinoma
      • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
      • TACE
      • Nanjing, China
      • +1 more
      Dec 28, 2022

      Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

      Recruiting
      • Advanced Lung Carcinoma
      • LK101 injection (personlized neoantigen pulsed DC vaccine )
      • +2 more
      • Beijing, Beijing, China
        Cancer hospital Chinese Academy of Medical Sciences
      May 23, 2023

      Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

      Recruiting
      • Hepatocellular Carcinoma
      • Shanghai, China
        Zhongshan Hospital Fudan university
      Jan 31, 2023

      Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

      Completed
      • Colorectal Cancer
      • Fruquintinib combined with anti-PD-1 antibodies
      • ChangSha, Hunan, China
        Hunan Cancer Hospital
      Aug 27, 2023

      Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

      Recruiting
      • Advanced Solid Tumor
      • Refractory Tumor
      • Suzhou, China
        The Second Affiliated Hospital of SchoowUniversity
      Mar 29, 2023

      High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

      Suspended
      • NSCLC Stage IV
      • NSCLC, Stage IIIC
      • Primary Immune Response (PIR) test by Biodesix, Inc.
      • San Carlos, California
      • +1 more
      Jan 26, 2023

      Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

      Not yet recruiting
      • Muscle-Invasive Bladder Carcinoma
      • +2 more
      • Guangzhou, Guangdong, China
        Cancer Center, Sun Yat-sen University
      Aug 3, 2023

      Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

      Active, not recruiting
      • Gastric or Gastroesophageal Junction Adenocarcinoma
      • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
      • Nanjing, Jiangsu, China
        Jiangsu Cancer Hospital
      Jul 4, 2023